ArticleInternational urology and nephrology2010
Paricalcitol reduces basal and lipopolysaccharide-induced (LPS) TNF-alpha and IL-8 production by human peripheral blood mononuclear cells.
Article in International urology and nephrology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 34 citations in OpenAlex.
- The influence of vitamin D analogs on calcification modulators, N-terminal pro-B-type natriuretic peptide and inflammatory markers in hemodialysis patients: a randomized crossover study.BMC nephrology · 2014Trial
- Increased telomerase activity and vitamin D supplementation in overweight African Americans.International journal of obesity (2005) · 2012Trial
- Association between Vitamin D Status and Mortality among Adults with Diabetic Kidney Disease.Journal of diabetes research · 2022Article
- Vitamin D as a Potential Preventive Agent For Young Women's Breast Cancer.Cancer prevention research (Philadelphia, Pa.) · 2021Review
- Exploring the potential effect of paricalcitol on markers of inflammation in de novo renal transplant recipients.PloS one · 2020Article
- Anti-Inflammatory Effects of Vitamin D on Human Immune Cells in the Context of Bacterial Infection.Nutrients · 2016Article
- Effects of Citral on Lipopolysaccharide-Induced Inflammation in Human Umbilical Vein Endothelial Cells.Inflammation · 2016Article
- Calcium-Vitamin D Co-supplementation Affects Metabolic Profiles, but not Pregnancy Outcomes, in Healthy Pregnant Women.International journal of preventive medicine · 2016Article
- Causes of Vitamin D Deficiency and Effect of Vitamin D Supplementation on Metabolic Complications in Obesity: a Review.Current obesity reports · 2015Review
- Factors affecting effectiveness of vaccination against hepatitis B virus in hemodialysis patients.World journal of gastroenterology · 2014Review
- Vitamin D improves inflammatory bowel disease outcomes: basic science and clinical review.World journal of gastroenterology · 2014Review
- Selective vitamin D receptor activation as anti-inflammatory target in chronic kidney disease.Mediators of inflammation · 2014Article
- Vitamin D in inflammatory diseases.Frontiers in physiology · 2014Review
- Vitamin D receptor gene polymorphisms are associated with obesity and inflammosome activity.PloS one · 2014Article
- Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients.BMC nephrology · 2012Article
- Vitamin D: something new under the sun.Clinical kidney journal · 2012Article
- Vitamin d receptor activators and clinical outcomes in chronic kidney disease.International journal of nephrology · 2011Article
- Vitamin D and cardiovascular risk.International urology and nephrology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionVitamin D and its analogues proved to exert immunomodulatory effects. Paricalcitol is a vitamin D analogue that is safe. It has been used for years in the treatment of secondary hyperparathyroidism in hemodialysis patients and, importantly, it is less calcemic than vitamin D. In this study the immunomodulatory/anti-inflammatory properties of paricalcitol were evaluated in vitro. SUBJECT AND
methodsTen healthy volunteers enrolled into the study. Peripheral blood mononuclear cells (PBMC) at a concentration of 10(6) cells per well were cultured for 48 h in the presence or not of lipopolysaccharide (LPS) (100 ng/ml) and in the presence or not of paricalcitol (10(-8) M). TNF-alpha and IL-8 were measured in the supernatants by ELISA.
resultsBasal TNF-alpha concentration (50.3 +/- 22 pg/ml) was reduced by paricalcitol (44.1 +/- 23.2 pg/ml). LPS increased TNF-alpha concentration (150.0 +/- 81.7 pg/ml), but paricalcitol reduced it (121.1 +/- 69.0 pg/ml). The effect of paricalcitol on IL-8 production was more profound. Basal IL-8 concentration (1926 +/- 455 pg/ml) was reduced by paricalcitol (1273 +/- 472 pg/ml). LPS increased IL-8 concentration (2361 +/- 385 pg/ml), but paricalcitol returned it to its basal level (1849 +/- 417 pg/ml).
conclusionThe in vitro inhibition of transforming growth factor alpha and interleukin 8 by paricalcitol confirms the immunomodulatory properties of this vitamin D analogue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.